Clinical Oncology Next Generation Sequencing Market Size, Share, Trends, Growth Outlook

Clinical Oncology Next Generation Sequencing Market is estimated to increase at a growth rate of 15.2% CAGR over the forecast period from 2024 to 2030.

 

The Clinical Oncology Next Generation Sequencing Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Technology (Whole Genome Sequencing, Whole Exome Sequencing, Targeted Sequencing & Resequencing Centrifuges), By Workflow (NGS Pre-Sequencing, NGS Sequencing, NGS Data Analysis), By Application (Screening, Companion Diagnostics, Others), By End-user (Hospitals, Clinics, Laboratories).

 

An Introduction to Clinical Oncology Next Generation Sequencing Market in 2024

The clinical oncology next-generation sequencing (NGS) market in 2024 addresses the demand for advanced genomic profiling technologies and molecular diagnostics used in oncology research, cancer diagnostics, and personalized treatment decision-making. NGS technologies enable comprehensive analysis of tumor genomes, detection of somatic mutations, identification of therapeutic targets, and monitoring of treatment response and disease progression. Market dynamics are driven by factors such as the increasing understanding of cancer genomics and tumor heterogeneity, the demand for precision medicine approaches in oncology, and advancements in NGS platforms and bioinformatics tools for data analysis and interpretation. Collaboration between NGS technology providers, oncologists, and clinical laboratories fosters innovation and market growth in clinical oncology NGS, supporting personalized cancer care and targeted therapy strategies for improved patient outcomes.

 

Clinical Oncology Next Generation Sequencing Market Trend: Advancements in Precision Oncology

A significant trend in the Clinical Oncology Next Generation Sequencing (NGS) market is the continuous advancements in precision oncology. NGS technologies enable comprehensive genomic profiling of tumors, allowing oncologists to identify genetic alterations associated with cancer development and progression. With the growing understanding of cancer biology and the emergence of targeted therapies and immunotherapies, there is an increasing emphasis on utilizing NGS for molecular profiling to guide personalized treatment strategies. As precision oncology continues to evolve, the demand for NGS-based tests in clinical oncology settings is expected to rise, driving market growth.

Clinical Oncology Next Generation Sequencing Market Driver: Growing Demand for Companion Diagnostics

A key driver for the Clinical Oncology NGS market is the growing demand for companion diagnostics. Companion diagnostics play a crucial role in oncology by identifying biomarkers that predict patient response to specific targeted therapies. NGS-based tests enable comprehensive genomic profiling, allowing for the identification of multiple biomarkers simultaneously. As targeted therapies become increasingly important in cancer treatment, the demand for companion diagnostics that can accurately identify patients who are likely to benefit from these therapies is rising. This drives the adoption of NGS-based tests in clinical oncology for molecular profiling and treatment decision-making.

Clinical Oncology Next Generation Sequencing Market Opportunity: Integration of Artificial Intelligence (AI)

One potential opportunity in the Clinical Oncology NGS market lies in the integration of artificial intelligence (AI) technologies. AI algorithms can analyze large-scale genomic and clinical data generated by NGS tests to identify complex patterns, predict treatment responses, and guide therapeutic decision-making. By harnessing AI-powered analytics, healthcare providers can enhance the interpretation of NGS results, improve risk stratification, and optimize treatment selection for cancer patients. Additionally, AI-driven approaches can accelerate biomarker discovery, facilitate drug development, and contribute to the advancement of precision oncology. Integrating AI into NGS workflows presents an opportunity to enhance the efficiency, accuracy, and clinical utility of genomic testing in oncology, driving further innovation and market growth.

 

Clinical Oncology Next Generation Sequencing Market Segmentation

By Technology

Whole Genome Sequencing

Whole Exome Sequencing

Targeted Sequencing & Resequencing Centrifuges

By Workflow

NGS Pre-Sequencing

NGS Sequencing

NGS Data Analysis

By Application

Screening

-Sporadic Cancer

-Inherited Cancer

Companion Diagnostics

Others

By End-user

Hospitals

Clinics

Laboratories

 

Geographical Analysis

North America (United States, Canada, Mexico)

Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)

Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

 

Clinical Oncology Next Generation Sequencing Market Companies

Agilent Technologies

Beijing Genomics Institute (BGI)

Caris Life Sciences

Eurofins Scientific S.E.

Exact Science

F. Hoffmann-La Roche Ltd

Foundation Medicine

Illumina Inc

Myriad Genetics

Oxford Nanopore Technologies Ltd

Pacific Bioscience

Partek Inc

Perkin Elmer

Qiagen N.V.

Thermo Fisher Scientific

 

Reasons to Buy the Clinical Oncology Next Generation Sequencing Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions

• Gain access to detailed insights on the Clinical Oncology Next Generation Sequencing Market, encompassing current market size, growth trends, and forecasts till 2030.

• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities

• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends

• Identify lucrative investment avenues and expansion opportunities within the Clinical Oncology Next Generation Sequencing Market industry, guided by robust, data-backed analysis.

• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics

• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain

• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics

• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

 

1 Introduction to 2024 Clinical Oncology Next Generation Sequencing Market

1.1 Market Overview

1.2 Quick Facts

1.3 Scope/Objective of the Study

1.4 Market Definition

1.5 Countries and Regions Analyzed

1.6 Units, Currency, and Conversions

1.7 Industry Value Chain

 

2 Research Methodology

2.1 Market Size Estimation

2.2 Sources and Research Methodology

2.3 Data Triangulation

2.4 Assumptions and Limitations

 

3 Executive Summary

3.1 Global Clinical Oncology Next Generation Sequencing Market Size Outlook, $ Million, 2021 to 2030

3.2 Clinical Oncology Next Generation Sequencing Market Outlook By Type, $ Million, 2021 to 2030

3.3 Clinical Oncology Next Generation Sequencing Market Outlook By Product, $ Million, 2021 to 2030

3.4 Clinical Oncology Next Generation Sequencing Market Outlook By Application, $ Million, 2021 to 2030

3.5 Clinical Oncology Next Generation Sequencing Market Outlook by Key Countries, $ Million, 2021 to 2030

 

4 Market Dynamics

4.1 Key Driving Forces of Clinical Oncology Next Generation Sequencing Market Industry

4.2 Key Market Trends in Clinical Oncology Next Generation Sequencing Market Industry

4.3 Potential Opportunities in Clinical Oncology Next Generation Sequencing Market Industry

4.4 Key Challenges in Clinical Oncology Next Generation Sequencing Market Industry

 

5 Market Factor Analysis

5.1 Competitive Landscape

5.1.1 Global Clinical Oncology Next Generation Sequencing Market Share by Company (%), 2023

5.1.2 Product Offerings by Company

5.2 Porter’s Five Forces Analysis

 

6 Growth Outlook Across Scenarios

6.1 Growth Analysis-Case Scenario Definitions

6.2 Low Growth Scenario Forecasts

6.3 Reference Growth Scenario Forecasts

6.4 High Growth Scenario Forecasts

 

7 Global Clinical Oncology Next Generation Sequencing Market Outlook By Segments

7.1 Clinical Oncology Next Generation Sequencing Market Outlook by Segments

By Technology

Whole Genome Sequencing

Whole Exome Sequencing

Targeted Sequencing & Resequencing Centrifuges

By Workflow

NGS Pre-Sequencing

NGS Sequencing

NGS Data Analysis

By Application

Screening

-Sporadic Cancer

-Inherited Cancer

Companion Diagnostics

Others

By End-user

Hospitals

Clinics

Laboratories

 

8 North America Clinical Oncology Next Generation Sequencing Market Analysis And Outlook To 2030

8.1 Introduction to North America Clinical Oncology Next Generation Sequencing Markets in 2024

8.2 North America Clinical Oncology Next Generation Sequencing Market Size Outlook by Country, 2021-2030

8.2.1 United States

8.2.2 Canada

8.2.3 Mexico

8.3 North America Clinical Oncology Next Generation Sequencing Market size Outlook by Segments, 2021-2030

By Technology

Whole Genome Sequencing

Whole Exome Sequencing

Targeted Sequencing & Resequencing Centrifuges

By Workflow

NGS Pre-Sequencing

NGS Sequencing

NGS Data Analysis

By Application

Screening

-Sporadic Cancer

-Inherited Cancer

Companion Diagnostics

Others

By End-user

Hospitals

Clinics

Laboratories

 

9 Europe Clinical Oncology Next Generation Sequencing Market Analysis And Outlook To 2030

9.1 Introduction to Europe Clinical Oncology Next Generation Sequencing Markets in 2024

9.2 Europe Clinical Oncology Next Generation Sequencing Market Size Outlook by Country, 2021-2030

9.2.1 Germany

9.2.2 France

9.2.3 Spain

9.2.4 United Kingdom

9.2.4 Italy

9.2.5 Russia

9.2.6 Norway

9.2.7 Rest of Europe

9.3 Europe Clinical Oncology Next Generation Sequencing Market Size Outlook By Segments, 2021-2030

By Technology

Whole Genome Sequencing

Whole Exome Sequencing

Targeted Sequencing & Resequencing Centrifuges

By Workflow

NGS Pre-Sequencing

NGS Sequencing

NGS Data Analysis

By Application

Screening

-Sporadic Cancer

-Inherited Cancer

Companion Diagnostics

Others

By End-user

Hospitals

Clinics

Laboratories

 

10 Asia Pacific Clinical Oncology Next Generation Sequencing Market Analysis And Outlook To 2030

10.1 Introduction to Asia Pacific Clinical Oncology Next Generation Sequencing Markets in 2024

10.2 Asia Pacific Clinical Oncology Next Generation Sequencing Market Size Outlook by Country, 2021-2030

10.2.1 China

10.2.2 India

10.2.3 Japan

10.2.4 South Korea

10.2.5 Indonesia

10.2.6 Malaysia

10.2.7 Australia

10.2.8 Rest of Asia Pacific

10.3 Asia Pacific Clinical Oncology Next Generation Sequencing Market size Outlook by Segments, 2021-2030

By Technology

Whole Genome Sequencing

Whole Exome Sequencing

Targeted Sequencing & Resequencing Centrifuges

By Workflow

NGS Pre-Sequencing

NGS Sequencing

NGS Data Analysis

By Application

Screening

-Sporadic Cancer

-Inherited Cancer

Companion Diagnostics

Others

By End-user

Hospitals

Clinics

Laboratories

 

11 South America Clinical Oncology Next Generation Sequencing Market Analysis And Outlook To 2030

11.1 Introduction to South America Clinical Oncology Next Generation Sequencing Markets in 2024

11.2 South America Clinical Oncology Next Generation Sequencing Market Size Outlook by Country, 2021-2030

11.2.1 Brazil

11.2.2 Argentina

11.2.3 Rest of South America

11.3 South America Clinical Oncology Next Generation Sequencing Market size Outlook by Segments, 2021-2030

By Technology

Whole Genome Sequencing

Whole Exome Sequencing

Targeted Sequencing & Resequencing Centrifuges

By Workflow

NGS Pre-Sequencing

NGS Sequencing

NGS Data Analysis

By Application

Screening

-Sporadic Cancer

-Inherited Cancer

Companion Diagnostics

Others

By End-user

Hospitals

Clinics

Laboratories

 

12 Middle East And Africa Clinical Oncology Next Generation Sequencing Market Analysis And Outlook To 2030

12.1 Introduction to Middle East and Africa Clinical Oncology Next Generation Sequencing Markets in 2024

12.2 Middle East and Africa Clinical Oncology Next Generation Sequencing Market Size Outlook by Country, 2021-2030

12.2.1 Saudi Arabia

12.2.2 UAE

12.2.3 Oman

12.2.4 Rest of Middle East

12.2.5 Egypt

12.2.6 Nigeria

12.2.7 South Africa

12.2.8 Rest of Africa

12.3 Middle East and Africa Clinical Oncology Next Generation Sequencing Market size Outlook by Segments, 2021-2030

By Technology

Whole Genome Sequencing

Whole Exome Sequencing

Targeted Sequencing & Resequencing Centrifuges

By Workflow

NGS Pre-Sequencing

NGS Sequencing

NGS Data Analysis

By Application

Screening

-Sporadic Cancer

-Inherited Cancer

Companion Diagnostics

Others

By End-user

Hospitals

Clinics

Laboratories

 

13 Company Profiles

13.1  Company Snapshot

13.2 SWOT Profiles

13.3 Products and Services

13.4 Recent Developments

13.5 Financial Profile

List of Companies

Agilent Technologies

Beijing Genomics Institute (BGI)

Caris Life Sciences

Eurofins Scientific S.E.

Exact Science

F. Hoffmann-La Roche Ltd

Foundation Medicine

Illumina Inc

Myriad Genetics

Oxford Nanopore Technologies Ltd

Pacific Bioscience

Partek Inc

Perkin Elmer

Qiagen N.V.

Thermo Fisher Scientific

 

14 Appendix

14.1 Customization Offerings

14.2 Subscription Services

14.3 Related Reports

14.4 Publisher Expertise

Clinical Oncology Next Generation Sequencing Market Segmentation

By Technology

Whole Genome Sequencing

Whole Exome Sequencing

Targeted Sequencing & Resequencing Centrifuges

By Workflow

NGS Pre-Sequencing

NGS Sequencing

NGS Data Analysis

By Application

Screening

-Sporadic Cancer

-Inherited Cancer

Companion Diagnostics

Others

By End-user

Hospitals

Clinics

Laboratories

 

Geographical Analysis

North America (United States, Canada, Mexico)

Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)

Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)